Enliven Therapeutics, Inc. (ELVN) stock
ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$44.89−1.96 (-4.18%)
Close on Nov 18, 2026Market cap $3.29BP/E –Yield –
Enliven Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Enliven Therapeutics's price to book ratio was 4.2× on Nov 11, 2026, against 2.7× a year earlier. Over the last 5 years it ranged from 0.2× to 7.4×, with a median of 2.8×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.2× | +2.3 |
| 2025 | Dec 31, 2025 | 1.9× | −1.8 |
| 2024 | Dec 31, 2024 | 3.7× | +1.5 |
| 2023 | Dec 29, 2023 | 2.2× | +2.0 |
| 2022 | Jan 31, 2022 | 0.2× | −0.1 |
| 2021 | Dec 31, 2021 | 0.3× | −1.7 |
| 2020 | Dec 31, 2020 | 1.9× | – |
See a number that looks wrong?